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Editorial	summary:	
Thirteen	algorithms	for	the	detection	of	cancer	driver	genes	at	the	sub-gene	level	are	assessed	
for	their	advantages	and	limitations.		
	 	
Abstract	
	
Understanding	genetic	events	that	lead	to	cancer	initiation and	progression	remains	one	of	the	biggest	
challenges	in	cancer	biology.	Traditionally,	most	algorithms	for	cancer-driver	identification	look	for	genes	
that	have	more	mutations	than	expected	from	the	average	background	mutation	rate.	However,	there	is	
now	a	wide	variety	of	methods	that	look	for	nonrandom	distribution	of	mutations	within	proteins	as	a	
signal	for	the	driving	role	of	in	cancer.	Here	we	classify	and	review	such	subgene-resolution	algorithms,	
compare	their	findings	on	four	distinct	cancer	data	sets	from	The	Cancer	Genome	Atlas	and	discuss	how	
predictions	from	these	algorithms	can	be	interpreted	in	the	emerging	paradigms	that	challenge	the	simple	
dichotomy	between	driver	and	passenger	genes.		
	 	
Introduction	
	
Cancer	is	a	heterogeneous	disease	that	is	driven	by	genomic	and	epigenomic	abnormalities.	Recent	efforts	
in	cancer	genomics	have	provided	us	with	a	catalog	detailing	such	abnormalities	in	tens	of	thousands	of	
human	cancers1.	This	catalog	has	significantly	expanded	our	understanding	of	the	molecular	aspects	of	
cancer.	However,	the	mutation	landscape	in	cancer	has	turned	out	to	be	extremely	complex2-4,	as	most	
tumors	have	hundreds	or	thousands	of	somatic	mutations	which	are	seldom	found	again	in	other	tumors.	
This	apparent	heterogeneity	is	usually	interpreted	within	the	driver-passenger	paradigm,	in	which	the	few	
recurrent	mutations	 are	 viewed	 as	 drivers	 of	 the	 oncogenic	 process	 that	 give	 cancer	 cells	 a	 selective	
advantage;	while	most	mutations,	especially	rare	ones,	are	viewed	as	passengers	that	have	no	significant	
consequences	for	the	cell5.		
	
There	are	many	possible	ways	to	identify	cancer-driver	events.	For	instance,	one	can	look	for	signals	of	
nonrandom	distribution	of	mutations	at	various	levels	of	biological	resolution,	spanning	from	individual	
positions	 in	 the	 protein6	 up	 to	whole	 genes5	 or	 pathways7	 (Fig.	 1a).	Many	 of	 the	 recently	 developed	
methods	 aim	 to	 find	 driver	 events	 at	 the	 subgene	 level.	 One	 advantage	 of	 such	 higher	 resolution	
approaches	 is	 that	 they	can	 identify	cases	when	different	mutations	 in	 the	same	gene	 lead	to	distinct	
phenotypes8.		
	
	
Figure	 1	 |	 Finding	mutation	 drivers	 across	 biological	 scales.	 (a)	 Schematic	 of	 different	 levels	 for	 cancer	 driver	
detection	and	the	tools	used.	(b)	The	four	groups	of	sub-gene	algorithms	according	to	the	type	of	regions	they	find	
and	their	number	of	dimensions.	(c)	Types	of	regions	detected	by	each	class	of	algorithm	based	on	EGFR	mutations	
in	glioblastoma.	
	
While	there	are	several	reviews	of	cancer-driver-detection	algorithms9,10,	to	the	best	of	our	knowledge	
none	have	focused	on	subgene-resolution	algorithms,	which	are	gaining	in	popularity.	Here	we	review,	
classify	and	compare	such	algorithms,	which	we	call	subgene	algorithms,	and	we	discuss	their	strengths	
and	weaknesses	based	on	their	results	on	four	different	cancer	data	sets.	Note	that	it	is	not	our	intention	
to	determine	which	methods	are	better,	as	this	is	something	that	likely	depends	on	the	type	of	question	
being	 asked,	 but	 rather	 to	 inform	potential	 users	 about	 how	 the	 different	 assumptions	 and	 technical	
choices	of	each	method	influence	their	results.	Next,	we	show	how	the	results	of	these	methods	can	be	
integrated	with	other	biological	data	to	gain	a	deeper	understanding	of	the	consequences	of	mutations	in	
these	driver	regions.	Finally,	we	discuss	the	implications	that	the	existence	of	such	mutation	clusters	might	
have	regarding	novel	ideas	in	cancer	biology,	such	as	expanding	the	drivers-passenger	paradigm	in	favor	
of	more	nuanced	or	even	continuous	models11-13.		
	
Results	
	
A	classification	of	mutation-clustering	algorithms	
	
While	the	overall	goal	of	all	subgene	driver-detection	algorithms	is	the	same—i.e.,	identifying	nonrandom	
mutation	clusters	in	cancer	genomes—the	details	of	their	implementations	and	some	of	their	assumptions	
can	vary	significantly.	For	example,	some	methods	rely	solely	on	protein	sequences14,15;	therefore,	they	
can	 only	 find	 clusters	 of	mutations	 that	 are	 linear	 in	 the	 primary	 sequence.	 Other	methods	 leverage	
information	from	3D	protein	structures	and	can	identify	spatial	patterns	that	are	discontinuous	along	the	
sequence6,16.	Similarly,	while	some	algorithms	only	use	the	position	of	 the	mutations	 (either	 in	one	or	
three	dimensions)	to	find	clusters	de	novo16,17,	others	focus	on	externally	defined	protein	regions	(such	as	
protein	domains18,19,	phosphorylation	sites20	or	interaction	interfaces21)	to	identify	those	regions	enriched	
in	somatic	mutations.	Based	on	these	two	criteria	(number	of	dimensions	and	use	of	externally	defined	
regions),	it	is	possible	to	classify	subgene	algorithms	into	four	different	groups	(Fig.	1b,c).	We	provide	an	
overview	(detailed	further	in	Supplementary	Table	1)	of	their	implementation,	statistical	approaches	and	
their	strengths	and	weaknesses.	
	
Type	I	–	De	novo	linear	clusters	
	
This	 category	 includes	methods	 that	 look	 for	 clusters	 along	 the	 gene	 sequence.	 The	main	 difference	
between	individual	methods	from	this	group	is	the	specific	background	model	they	use.	While	there	are	
methods	that	rely	solely	on	statistical	models15,22,	most	Type	1	methods	are	designed	to	integrate	other	
biological	signals,	such	as	the	distribution	of	silent	mutations14,23,	the	ratio	between	the	different	types	of	
mutations	occurring	in	a	specific	gene24,	the	probability	of	each	mutation	given	the	nucleotide	before	and	
after	the	mutated	position25,26	or	by	kernel-density	estimates	across	multiple	biologically	relevant	scales27.		
	
Type	II	–	De	novo	three-dimensional	clusters	
	
These	algorithms	find	novel	mutation	clusters	using	 information	about	the	3D	structure	of	the	protein	
encoded	 by	 a	 given	 gene.	 Their	 scope	 is	 more	 limited	 than	 that	 Type	 I	 algorithms,	 because	 Type	 II	
algorithms	 can	 only	 be	 applied	 to	 proteins	whose	 3D	 structure	 is	 either	 known	or	 can	 be	 reasonably	
predicted.	While	experimentally	determined	structures	are	only	available	for	approximately	6,100	human	
proteins,	the	structural	coverage	can	be	extended	to	over	13,000	proteins28	by	aligning	proteins	to	their	
close	homologs	with	experimental	structures	(Supplementary	Fig.	1).		
	
The	biggest	differences	between	Type	II	algorithm	methods	are	in	how	such	methods	interpret	structural	
data	to	find	mutation	clusters.	Some	tools	analyze	a	reordered	version	of	the	protein’s	sequence	based	
on	 the	 distance	 between	 residues	 in	 3D29	 or	 use	 network	 algorithms	 on	 the	 graph	 derived	 from	 the	
structure30.	 However,	 most	 Type	 II	 algorithms	 are	 designed	 to	 identify	 3D	 clusters	 using	 the	 protein	
structure	 directly	 and	 to	 calculate	 empirical	 P	 values	 by	 reshuffling	 the	mutations	 in	 the	 structure31.	
Nevertheless,	 the	 specific	 details	 of	 Type	 II	 algorithms	 can	 be	 very	 different,	 as	 some	 use	 spheres	 of	
varying	 radii32,	while	others	use	 the	closeness	 in	 the	structure-derived	 residue	network6,	 the	Shannon	
entropy	of	the	region17	or	weighted-scoring	functions16.	Finally,	while	most	methods	can	focus	solely	on	
individual	proteins,	others	are	capable	of	finding	3D	clusters	that	span	across	protein	complexes17.		
	
Type	III	–	Linear	externally-defined	regions	
	
This	group	contains	algorithms	that	analyze	externally	defined	linear	protein	regions	to	identify	those	that	
are	enriched	in	cancer	somatic	mutations.	Therefore,	unlike	Type	I	algorithms,	these	methods	can	only	be	
applied	to	proteins	where	at	least	one	functional	region	is	known,	and	this	currently	limits	their	scope	to	
approximately	 65%	 of	 the	 human	 proteome	 (Supplementary	 Fig.	 1).	 These	 regions	 can	 be	 protein	
domains18	or	post-translational	modification	sites20.	Type	III	algorithms	compare	the	number	of	mutations	
in	the	selected	region	with	that	of	the	rest	of	the	protein	to	determine	whether	there	is	enrichment	in	
somatic	mutations	 in	 specific	domains	or	 regions.	We	also	 include	 in	 this	category	methods	 that	align	
multiple	 instances	 of	 the	 same	domain	 in	 different	 proteins	 to	 find	 commonly	mutated	 positions19,33.	
These	methods	are	based	on	the	rationale	that	mutations	in	equivalent	positions	of	the	same	domain	will	
have	the	same	effect	on	function.	These	analyses	have	revealed	strikingly	similar	mutation	patterns	across	
domain	families	such	as	kinases	or	the	EGF	and	FGF	receptor	families33.		
	
Type	IV	–	Three-dimensional	externally-defined	regions	
	
Type	IV	algorithms	find	3D	externally-defined	regions	that	are	enriched	in	somatic	mutations.	To	the	best	
of	our	knowledge,	this	category	currently	includes	only	e-Driver3D21	and	a	separate	module	of	CLUMPS16	
(not	used	here)	that	uses	structurally	resolved	interaction	data.	This	category	 is	most	 limited	in	scope,	
because	both	structural	data	and	defined	functional	regions	are	required	for	the	application	of	Type	IV	
algorithms.	For	example,	in	the	case	of	e-Driver3D,	which	currently	analyzes	protein	interaction	interfaces,	
these	limitations	exclude	all	proteins	that	are	not	involved	in	structurally	resolved	complexes.	In	the	case	
of	 CLUMPS,	 the	 number	 of	 proteins	 and	 structures	 that	 can	 be	 analyzed	 is	 higher,	 as	 CLUMPS	 uses	
information	 regarding	 interfaces	with	DNA,	RNA,	 ion	 ligands	or	 small	molecules	 in	addition	 to	protein	
partners.	However,	methods	in	this	category	exploit	most	biological	information	and,	therefore,	provide	
the	highest	functional	information	on	the	mutation	clusters	they	identify.		
	
Same	category	methods	identify	similar	sets	of	genes		
	
In	 order	 to	 explore	 the	 strengths	 and	 limitations	 of	 each	 of	 these	 four	 categories,	 we	 compared	 the	
predictions	of	methods	covering	all	four	categories,	as	well	as	predictions	of	two	methods	that	rely	on	
whole-gene	analysis	(OncodriveFM	and	MutSigCV)5,34,	on	four	different	cancer	genomics	data	sets	from	
The	Cancer	Genome	Atlas1.	We	aimed	 to	 assess	 how	 the	 specific	 assumptions	 behind	 each	 algorithm	
affect	the	number	and	type	of	drivers	it	identifies.	In	our	analysis,	we	include	five	methods	that	belong	to	
Type	 I	 (Hotspot35,	 NMC15,	 OncodriveCLUST14,	MutSig-CL26	 and	 iSIMPRe22),	 four	 from	 Type	 II	 (iPAC29,	
GraphPAC30,	SpacePAC32	and	CLUMPS16),	three	from	Type	III	(e-Driver18,	ActiveDriver20	and	LowMACA19)	
and	one	from	Type	IV	(e-Driver3D21).		
Our	 results	 show	 similarities	 between	 algorithms	 that	 belong	 to	 the	 same	 category	 (Fig.	 2a,	
Supplementary	Figs.	2–4	and	Supplementary	Tables	2–5).	For	example,	most	Type	I,	Type	II	and	Type	III	
algorithms	tend	to	cluster	together	in	all	data	sets.	Nevertheless,	each	group	seems	to	have	its	own	outlier	
methods.	In	the	case	of	Type	I	algorithms,	for	example,	NMC	does	not	cluster	with	the	other	methods	in	
the	case	of	BRCA,	GBM	and	LUAD.	In	the	case	of	Type	II	algorithms,	CLUMPS	predictions	are	very	different	
from	those	of	the	family	of	PAC	algorithms	in	BLCA,	BRCA	and	GBM.	Finally,	ActiveDriver	also	seems	to	
identify	different	genes	than	the	other	 two	Type	 III	algorithms	 in	all	data	sets.	The	reasons	why	these	
algorithms	behave	differently	 from	 the	 rest	 of	methods	 from	 the	 same	 category	 could	 be	 varied.	 For	
example,	 in	 the	 case	 of	 ActiveDriver,	 it	 could	 be	 because	 this	 algorithm	 analyzes	 post-translational	
modification	sites,	unlike	the	other	two	Type	III	algorithms,	which	focus	on	protein	domains.	Therefore,	
these	tools	could	be	finding	complementary	sets	of	genes	that	drive	cancer	through	distinct	mechanisms.	
	
	
	
Figure	2	|	Comparison	of	the	overall	predictions	of	each	method.	(a)	Principal	component	analysis	of	the	predictions	
by	each	method	in	the	four	distinct	datasets	using	the	p-values	for	all	the	genes	detected	at	least	by	one	algorithm.	
(b)	Predictions	in	the	glioblastoma	dataset	by	each	method	(left	panel)	and	grouped	by	categories	(second	panel).	
Methods	are	clustered	according	to	the	genes	they	detect.	Due	to	space	limitations,	we	only	show	genes	that	are	
either	detected	by	at	least	four	different	algorithms	or	detected	by	a	single	algorithm	and	that	are	included	in	the	
Cancer	Gene	Census	as	missense	drivers.	We	also	show	the	structural	coverage	of	these	genes	(third	panel),	whether	
they	are	known	driver	genes	(fourth	panel)	and	whether	they	are	oncogenes	(OG),	tumor	suppressor	genes	(TSG),	
both	(OG/TSG)	or	known	cancer	genes	whose	mode	of	action	still	needs	to	be	determined	(Unk).	Finally,	we	also	
show	the	number	of	mutations	of	each	gene	(right	panel).	
	
In	terms	of	specific	predictions,	most	algorithms	identify	the	most	frequently	mutated	cancer	driver	genes	
in	the	different	cancer	types.	For	example,	all	methods	identify	EGFR	and	TP53	as	GBM	driver	genes,	all	
but	two	find	PIK3CA,	and	all	but	three	identify	IDH1	(Fig.	2b).	However,	results	for	other	genes	exemplify	
the	 complementarity	 between	methods	 from	different	 categories.	 Again,	 in	 the	 case	 of	GBM,	 Type	 II	
algorithms	 do	 not	 detect	 PIK3R1,	 because	 the	 missense	 mutations	 are	 spread	 throughout	 a	 large	
interface.	However,	Type	I,	Type	III	or	Type	IV	algorithms	detect	the	mutation	cluster	PIK3R1,	even	if	the	
clusters	 predicted	by	 each	method	differ	 slightly	 in	 its	 exact	 size	 and	position.	 In	 other	 cases,	 certain	
proteins	are	missed	by	some	methods	simply	because	the	methods	lack	statistical	power	at	the	selected	
significance	threshold.	For	example,	BRAF,	a	known	driver	gene	in	various	cancer	types,	is	also	detected	
as	a	potential	driver	in	glioblastoma	by	most	subgene	algorithms	but,	interestingly,	not	by	the	algorithms	
that	work	at	the	whole-gene	level,	OncodriveFM	and	MutSigCV.	A	possible	explanation	for	this	could	be	
the	low	mutation	frequency	of	BRAF	in	this	cancer	type	(eight	mutations	in	363	samples),	which	makes	it	
difficult	to	detect	when	comparing	its	frequency	to	that	of	other	genes.	Nevertheless,	six	of	these	eight	
mutations	happen	in	the	residue	V600,	making	the	cluster	of	mutations	in	BRAF	amenable	for	detection	
with	various	subgene	algorithms.	In	fact,	many	genes	detected	only	by	subgene	algorithms,	regardless	of	
their	category,	have	relatively	low	mutation	frequencies	when	compared	with	genes	identified	by	whole-
gene	algorithms	(Fig.	2b).		
		
Structure-based	methods	have	high	precision	but	low	recall	
	
We	estimated	the	precision	and	recall	values	for	each	method	and	category	in	each	data	set	using	the	list	
of	genes	from	the	Cancer	Gene	Census	(CGC)36	that	are	known	to	play	a	driver	role	in	each	cancer	type.	
The	overall	results	per	category	show	that	whole-gene	methods	have	higher	recall	than	any	of	the	subgene	
categories	in	all	four	data	sets	we	studied	(Fig.	3a).	This	supports	the	idea	that	the	whole-gene	methods	
capture	classical	driver	genes.	In	terms	of	precision,	however,	whole-gene	methods	show	similar	or	lower	
values	than	those	of	the	structure-based	algorithms	(Types	II	and	IV).		
	
Figure	3	|	Evaluating	the	predictions	of	each	method	and	type	of	algorithms	based	on	CGC	data.	(a)	Recall	(left)	
and	precision	(right)	values	for	each	method	category	in	each	dataset	(top)	and	each	algorithm	(bottom).	(b)	Known	
driver	role	of	the	detected	genes	by	each	method	according	to	CGC	in	each	dataset.	
	
As	 for	 the	 individual	methods,	we	 observe	 a	 clear	 split	 in	 recall	 values	 between	 the	 two	whole-gene	
methods	and	any	of	the	subgene	algorithms,	with	the	former	having	higher	recall	values	than	those	of	the	
latter.	 In	 our	 opinion,	 there	 are	 likely	 two	 explanations	 for	 this	 result.	 The	 first	 is	 that	 whole-gene	
algorithms	detect	both	tumor	suppressors	and	oncogenes,	whereas	subgene	algorithms	are	more	likely	
to	detect	oncogenes	(see	below).	The	second	is	that,	when	compared	to	the	rest	of	the	genome,	most	
genes	in	the	gold-standard	list	have	been	defined	based	on	their	mutation	recurrence—the	signal	that	
whole-gene	methods	 look	for.	Subgene	algorithms,	however,	are	designed	to	detect	mutation	clusters	
and	take	 into	account	only	 the	mutations	within	a	specific	gene.	While	 this	gives	an	advantage	to	 the	
subgene	algorithms	 in	cases	of	 low	mutation	frequencies	(such	as	BRAF	 in	glioblastoma),	 it	 is	not	how	
most	cancer	driver	genes	have	been	defined	until	now.	Within	subgene	methods,	we	observe	higher	recall	
values	for	Type	I	algorithms	than	for	the	rest,	probably	because	Type	I	algorithms	can	be	applied	to	any	
gene.	When	analyzing	the	precision	data,	we	found	two	groups	of	methods,	with	CLUMPS,	the	two	e-
Driver	versions	and	Hotspot	making	the	group	with	higher	precision	values.		
	
Sub-gene	methods	identify	new	roles	for	known	cancer	genes	
	
Intrigued	 by	 the	 relatively	 low	 precision	 values	 of	 most	 subgene	 algorithms,	 we	 classified	 the	 genes	
identified	 by	 each	method	 into	 different	 categories	 (Fig.	 3b)	 depending	 on	 whether	 they	 are	 known	
somatic	drivers	in	that	specific	tissue	and	whether	they	are	affected	by	missense	mutations	or	through	
other	genomic	alterations	 (such	as	copy-number	variations	or	genomic	 rearrangements).	As	expected,	
many	of	 the	 identified	genes	are	known	 to	be	missense	 somatic	drivers	 in	 their	 corresponding	 tissue.	
However,	there	are	also	231	genes	that	are	predicted	to	be	drivers	by	at	least	one	method	and	that,	while	
they	do	not	have	any	known	driver	 roles	 in	 the	tissue	where	they	are	detected,	 they	are	 identified	as	
drivers	 in	 other	 tissues.	 A	 total	 of	 123	of	 these	 genes	 (53%)	 are	missed	by	whole-gene	methods	 but,	
nonetheless,	are	detected	by	subgene	algorithms	(Supplementary	Table	6).		
	
To	 our	 surprise,	 subgene	 algorithms	 also	 detected	 genes	whose	 driver	 role	 is	 known	 but	 are	 usually	
affected	by	copy-number	variations	or	genomic	rearrangements.	For	example,	PDGFRB	acts	as	a	driver	in	
a	variety	of	leukemias	via	translocations;	however,	iPAC,	GraphPAC,	SpacePAC	and	MutSig-CL	all	detected	
PDGFRB	as	a	potential	driver	in	GBM	due	to	a	cluster	of	mutations	in	its	kinase	domain.	Similarly,	FGFR1	
has	 been	 linked	 to	 breast	 cancer	 when	 amplified	 and	 to	 myeloproliferative	 syndromes	 when	 trans-	
located.	Nevertheless,	both	ActiveDriver	and	LowMACA	identified	a	small	cluster	of	mutations	in	its	kinase	
domain.	Another	unexpected	finding	was	that	several	genes	known	to	cause	cancer	through	germline	(but	
not	somatic)	mutations	were	 identified	by	some	of	 the	methods.	The	most	significant	example	of	 this	
category	is	CDK4.	Germline	mutations	in	this	gene	are	associated	with	familial	melanoma,	but	six	subgene	
algorithms	 identified	 CDK4	 as	 a	 likely	 driver	 in	 lung	 adenocarcinoma.	 Notably,	 some	 of	 the	 somatic	
mutations	affect	 the	 same	amino	acids	as	 the	germline	variations	associated	with	melanoma,	 such	as	
R24L.	
	
Regarding	 the	mode	of	 action	of	 the	detected	 genes,	 it	 has	 previously	 been	 suggested	 that	mutation	
clusters	 are	 more	 frequent	 in	 oncogenes,	 whereas	 tumor	 suppressor	 genes	 have	 more	 distributed	
mutation	patterns17	(although	this	notion	has	been	questioned	by	recent	studies16).	Our	results	support	
the	original	observation,	as	all	the	subgene	algorithms,	regardless	of	the	type,	identify	more	oncogenes	
than	tumor	suppressor	genes	(Supplementary	Fig.	5).	 In	fact,	when	combining	the	predictions	from	all	
four	data	sets,	there	 is	a	statistically	significant	enrichment	of	oncogene	recognition	between	1.4-	and	
3.7-fold	in	all	subgene	algorithms	(two-sided	Fisher’s	test;	P	<	0.01).	Whole-gene	methods,	on	the	other	
hand,	do	not	seem	to	show	such	bias	and	detect	both	tumor	suppressor	genes	as	well	as	oncogenes.		
	
Sub-gene	algorithms	find	mutation	clusters	in	novel	driver	genes	
	
Most	subgene	methods	identify	nonrandom	mutation	distributions	in	many	genes	that	are	not	part	of	the	
CGC	(Fig.	3b).	It	is	likely	that	some	of	these	genes	will	be	false	positives,	but	many	could	be	true	driver	
genes	that	are	missed	by	whole-gene	methods.	Just	in	the	four	cancer	data	sets	that	we	studied,	there	
are	66	genes	that	are	not	yet	known	to	be	somatic	drivers	and	that	have	been	detected	by	at	least	three	
different	subgene	methods	but	not	by	 the	methods	 that	work	at	 the	gene	resolution	 (Supplementary	
Table	7).		
Though	they	are	not	yet	part	of	the	CGC,	some	of	these	genes	have	been	reported	to	have	roles	in	cancer	
or	are	 likely	 to	have	them	given	their	biological	 functions.	For	example,	OncodriveCLUST,	Hostpot	and	
ActiveDriver	all	detected	clusters	of	mutations	in	CSNK2A1	in	lung	adenocarcinoma.	This	protein	is	the	
catalytic	subunit	of	the	casein	kinase	II,	a	serine–threonine	kinase	involved	in	several	pathways	that	are	
important	in	cancer,	such	as	Wnt–CTNNB1	(ref.	37)	or	apoptosis38.	Similarly,	three	algorithms	detected	a	
cluster	 of	mutations	 in	PARP4	 in	 the	breast	 adenocarcinoma	data	 set	 (Supplementary	 Fig.	 3).	 Recent	
reports	suggest	that	germline	mutations	in	PARP4	might	increase	the	risk	of	thyroid	cancer	and	breast	
adenocarcinoma39,	thus	we	believe	that	this	gene	could	play	an	important	role	in	these	cancer	types.	
	
Overall,	while	one	needs	to	be	cautious	when	interpreting	these	gene	lists,	and	further	evidence	is	needed	
before	the	exact	role	of	these	genes	and	mutations	in	cancer	is	clear,	we	believe	that	subgene	algorithms	
can	identify	valuable	potential	cancer	driver	genes	missed	by	approaches	that	analyze	mutation	data	at	
other	biological	scales.		
	
Toward	a	continuum	model	of	cancer	mutations	
	
Only	a	small	number	of	cancer	mutations	have	well-defined	and	confirmed	functional	consequences.	Most	
do	not,	and	they	are	usually	referred	to	as	variants	of	unknown	significance	(VUS),	as	their	driver	effects	
are	 unknown.	 Many	 of	 such	 VUS	 are	 part	 of	 mutation	 clusters	 recognized	 as	 drivers	 by	 subgene	
algorithms,	and	this	immediately	raises	the	question	whether	these	mutations	can	act	as	drivers	in	the	
patients	that	carry	them.	Even	though	it	is	now	possible	to	systematically	test	some	of	these	mutations	
experimentally40,	 the	 most	 frequent	 approach	 to	 prioritize	 VUS	 in	 cancer-driver	 genes	 still	 involves	
bioinformatics	tools	that	predict	the	impact	of	such	mutations	on	the	function	of	the	protein41,42	or	map	
them	into	3D	structures43,44.		
	
Subgene	algorithms	also	provide	an	obvious	way	for	researchers	to	predict	the	impact	of	these	variants	
and	prioritize	them.	Since	most	of	these	methods	identify	specific	clusters	of	positions	within	the	protein,	
one	can	hypothesize	that	mutations	 in	these	positions	are	the	most	 likely	to	be	carcinogenic;	whereas	
mutations	located	in	other	protein	regions	are	less	likely	to	have	any	significant	driver	effect.	The	power	
of	this	classification	has	been	exemplified	in	the	analysis	of	EGFR	mutations	in	glioblastoma.	There	is	a	
correlation	between	the	location	of	EGFR	mutations	in	glioblastoma	and	the	overall	level	of	EGFR	protein	
as	well	as	EGFR	phosphorylation	levels21	(Fig.	4a–c).	Samples	with	mutations	in	the	dimerization	interface	
have	 the	highest	EGFR	protein	and	phosphorylation	 levels,	 suggesting	a	higher	activation	of	 the	EGFR	
pathway,	while	those	with	mutations	in	other	EGFR	regions	have	an	intermediate	phenotype	between	the	
interface-mutated	and	the	EGFR	wild-type	samples,	a	result	that	has	recently	been	verified	using	cancer	
cell	 lines6.	 This	 is	 consistent	with	 the	 role	of	 interface	and	hotspot	muta-	 tions	 acting	 as	major-driver	
events	and	with	other	EGFR	mutations	having	a	different	role	in	cancer.	To	the	best	of	our	knowledge,	
this	phenomenon	has	not	been	widely	studied	and	this	is	one	of	the	few	cases	analyzed	in	more	detail16.	
We	believe	that	subgene	algorithms	will	be	key	in	exploring	such	effects.	
	
Another	important	point	is	that	the	results	of	these	algorithms	can	also	be	interpreted	as	an	emerging	
challenge	to	the	driver–	passenger	paradigm.	Interestingly,	conceptual	doubts	about	this	paradigm	have	
been	formulated	for	many	years.	For	instance,	it	was	proposed	that	some	drivers	may	play	a	role	only	in	
spe-	cific	circumstances—thus	these	drivers	were	dubbed	as	latent12	or	mini-drivers13;	or	they	were	simply	
considered	part	of	a	con-	tinuum	of	cancer-promoting	mutations,	each	with	a	relatively	small	but	additive	
effect11.	Regardless	of	the	specifics,	all	these	models,	at	their	core,	expand	on	the	binary	driver–passenger	
paradigm	to	move	toward	a	more	nuanced	classification	in	which	mutations	and	the	genes	they	affect	can	
have	different	degrees	of	 contribution	 to	 cancer	 growth.	 The	 results	of	 subgene	algorithms	provide	a	
natural	way	to	classify	mutations	in	well-established	cancer-driver	genes	as	either	mutations	that	happen	
in	clusters	or	hotspots	(and	more	likely	to	be	major	drivers)	and	those	that	happen	in	other	regions	of	the	
same	protein	and	are	 less	frequently	mutated	(more	 likely	to	have	a	 lower	driver	effect	or	to	even	be	
passengers).	 Subgene	 algorithms	 also	 identify	 many	 genes	 that	 are	 potential	 low-frequency	 cancer-
drivers;	nevertheless,	such	genes	could	be	important	in	specific	cases,	and	the	study	of	these	genes	could	
lead	to	actionable	predictions	as	to	the	molecular	mechanism	of	specific	tumors	they	are	found	in.		
	
	
	
Figure	4	|	Using	mutation	clusters	to	improve	the	definition	of	cancer	drivers.	(a)	Glioblastoma	mutations	in	EGFR	
located	in	the	dimerization	interface	(in	red)	or	in	other	EGFR	positions	(yellow).	(b)	Classification	of	glioblastoma	
samples	depending	on	whether	they	have	mutations	in	the	EGFR	cluster	detected	by	each	method	(in	red)	or	other	
EGFR	mutations	(in	orange).	Each	row	corresponds	to	a	method	and	each	column	to	a	patient.	(c)	Comparing	protein	
levels	measured	by	RPPA	of	EGFR	 (left	panel),	EGFR	pY992	 (second	panel),	EGFR	pY1068	 (third	panel)	and	EGFR	
pY1173	(right	panel).	Samples	are	classified	according	to	whether	they	have	a	mutation	in	the	EGFR-EGFR	interface	
(in	red),	other	EGFR	mutations	(in	orange)	or	no	EGFR	mutations	(in	gray).	
	
Discussion	
	
Integrating	the	results	of	these	algorithms	with	other	omics	data	sets	will	likely	have	broad	implications	
for	 cancer	 research,	 including,	 but	 not	 limited	 to,	 advancing	 the	 continuing	 efforts	 to	 define	 how	
mutations	contribute	to	cancer	onset	and	progression.		
	
Also,	 while	 we	 have	 not	 explicitly	 explored	 this	 issue,	 it	 would	 likely	 be	 possible	 to	 apply	 the	 same	
classification	 (de	 novo	 or	 externally	 defined	 and	 linear	 or	 3D)	 to	 algorithms	 that	 detect	 clusters	 of	
noncoding	driver	mutations.	In	fact,	some	of	the	algorithms	discussed	here	have	also	been	successfully	
applied	to	the	analysis	of	noncoding	regions25,	where	they	have	 identified	several	mutation	clusters	 in	
promoters	and	5ʹ	UTRs,	among	other	noncoding	regions.	Given	the	relevance	of	noncoding	mutations	in	
can-	cer45,	this	will	be	an	important	issue	as	whole-genome	sequencing	becomes	more	widespread.	
	
Finally,	to	address	the	issue	of	long-term	sustainability	of	the	benchmarking	effort	initiated	here,	we	plan	
to	 incorporate	 the	 methods,	 input,	 output	 and	 gold-standard	 data	 sets	 into	 the	 pan-European	
bioinformatics	 infrastructure	 ELIXIR.	 ELIXIR	 is	 currently	 developing	 a	 data	 warehouse	 for	 hosting	
continuous	 automated	 benchmarking	 efforts	 in	 this	 and	 other	 areas	 of	 life	 sciences;	 for	 example,	
homology	building,	in	close	collaboration	with	different	research	communities.	The	current	ELIXIR	data	
warehouse,	 which	 includes	 documentation	 and	 further	 development	 plans,	 is	 accessible	 at	
http://elixir.bsc.es.		
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Online	Methods	
	
Mutation	data	analysis	and	preprocessing.	We	compared	the	predictions	of	methods	covering	all	four	
categories	to	explore	the	strengths	and	limitations	of	each	of	them.	For	Type	I	we	used	Hotspot35,	NMC15,	
OncodriveCLUST14,	MutSig-CL26	and	iSIMPRe22.	In	Type	II	we	included	iPAC29,	GraphPAC30,	SpacePAC32	and	
CLUMPS16.	For	Type	III	we	included	e-Driver18,21,	ActiveDriver20	and	LowMACA19.	Finally,	we	used	one	Type	
IV	algorithm,	e-Driver3D18,21,	as	well	as	two	methods	that	rely	on	whole-gene	analysis5,12.	We	analyzed	
four	different	cancer	genomics	data	sets	from	The	Cancer	Genome	Atlas:	glioblastoma	(GBM,	n	=	363)46,	
breast	 adenocarcinoma	 (BRCA,	 n	 =	 982)47,	 bladder	 adenocarcinoma	 (BLCA,	 n	 =	 137)48	 and	 lung	
adenocarcinomas	 (LUAD,	 n	 =	 546)49.	 We	 used	 Intogen50	 to	 predict	 the	 location	 and	 impact	 of	 each	
mutation	 in	 the	 different	 protein	 isoforms	 from	 their	 genomic	 coordinates	 (Supplementary	 Fig.	 6).	
Mutation	 data	 came	 from	 ref.	 35	 instead	 of	 the	 TCGA	 portal,	 as	 it	 had	 all	 the	 necessary	 additional	
information	for	each	mutation	in	order	to	run	the	Hotspot	algorithm.	
	
Algorithms.	We	ran	all	algorithms	using	their	default	settings.	In	the	case	of	the	Hotspot	algorithm,	we	
used	the	genomic	information	of	each	mutation	provided	in	the	original	publication.	For	Type	II	methods,	
when	there	were	multiple	3D	structures	that	could	be	used	as	templates	to	map	the	mutations,	we	chose	
the	structures	that	had	the	highest	structural	divergence	as	defined	by	PDBFlex51.	This	limits	the	impact	
of	multiple-testing	issues	and	also	ensures	that	we	captured	proteins	that	could	be	affected	by	protein	
flexibility.	In	the	case	of	ActiveDriver,	we	used	all	the	post-translational-modification	sites	provided	with	
the	algorithm:	phosphorylations,	acetylations	and	ubiquitinations.	For	e-Driver	and	e-Driver3D	we	used	
the	PFAM	domains,	disordered	regions	and	protein	interfaces	described	in	the	original	publications.	
	
Evaluation	 of	 the	 results.	 We	 used	 the	 list	 of	 genes	 included	 in	 the	 Cancer	 Genome	 Census36	
(downloaded	on	September	12,	2016)	as	benchmark	to	compare	the	performance	of	the	algorithms	on	
known	driver	genes.	We	limited	the	list	of	genes	to	those	that	were	defined	as	somatic	and	that	had	at	
least	five	mutations	in	the	data	set	being	studied.	We	defined	a	gene	as	predicted	by	an	algorithm	if	its	
FDR	value	was	below	0.05.	The	mode	of	action	was	also	obtained	from	the	CGC	 list.	Note	that	known	
cancer	genes	that	are	not	described	as	somatic	(i.e.,	only	as	germline)	or	as	drivers	in	other	tissues	in	CGC	
are	considered	as	not	known	for	the	purposes	of	the	evaluation.		
	
Regarding	the	PCA	analysis,	for	each	tissue	we	created	a	matrix	with	all	the	genes	detected	by	at	least	two	
algorithms	and	the	P	values	obtained	by	each	method	for	each	gene.	For	the	pur-	poses	of	this	analysis,	
all	the	missing	P	values	(e.g.,	genes	with	no	structures	have	no	P	values	for	Type	II	or	Type	IV	algorithms)	
were	assumed	to	be	1.	We	calculated	the	PCA	with	the	minus	logarithm	of	the	matrix.	The	list	of	candidate	
novel	driver	genes	identified	solely	by	subgene	methods	was	limited	only	to	those	genes	identified	by	at	
least	 three	 different	 algorithms.	 This	 threshold	 was	 defined	 to	 minimize	 the	 risk	 of	 overfitting.	 This	
approach	has	previously	proven	useful	in	detecting	cancer	driver	genes52.		
	
EGFR	 RPPA	 analysis.	We	 downloaded	 the	 normalized	 glioblastoma	 RPPA	 data	 from	 the	UCSC	 Cancer	
Genome	 Browser53	 and	 compared	 the	 levels	 of	 EGFR-R-C	 (overall	 EGFR),	 EGFR_pY1068-R-V	 (EGFR	
phosphorylated	 at	 Y1068),	 EGFR_pY1173-	 R-C	 (EGFR	 phosphorylated	 at	 Y1173)	 and	 EGFR_pY992-R-V	
(EGFR	phosphorylated	at	Y992)	in	three	different	groups	of	patients:	those	with	mutations	in	the	EGFR–
EGFR	interface	(based	on	the	PDB	coordinates	file	3NJP,	chains	A	and	B),	those	with	other	EGFR	mutations	
and	those	with	no	mutations	in	EGFR.	We	compared	protein	expression	levels	using	a	two-sided	Wilcoxon	
test.		
	
Data	availability	statement.	All	the	algorithms	reviewed	here	can	be	downloaded	from	the	sites	indicated	
at	Supplementary	Table	1.	The	code	and	data	used	to	compare	the	algorithms	and	generate	Figures	2–4	
can	be	obtained	at	https://github.com/eduardporta/sub-gene_resolution.		
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